Skip to content

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01942759
Enrollment
43
Registered
2013-09-16
Start date
2013-09-30
Completion date
2014-06-30
Last updated
2014-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Breast Neoplasms, Positron-Emission Tomography, Diffusion Magnetic Resonance Imaging

Brief summary

The purpose of this study is to determine findings of positron emission tomography and diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast cancer and compare of two imaging modality in these patients.

Detailed description

We aimed that to correlate both primary lesion 18F-fluorodeoxyglucose (FDG) maximum standardized uptake value (SUVmax) and diffusion-weighted imaging (DWI) apparent diffusion coefficient (ADC) with clinicopathological prognostic factors and compare the prognostic value of these indexes in breast cancer in this study. The evaluated and compared parameters are SUVmax and ADC according to age, tumour size, lymph node metastasis, receptor status, histologic grade, modified Nottingham prognostic index.

Interventions

None listed

Sponsors

Bagcilar Training and Research Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Newly diagnosis of breast cancer for which surgical intervention is planned

Exclusion criteria

* patients received neoadjuvant chemotherapy * before breast surgery

Design outcomes

Primary

MeasureTime frame
To evaluate the relationships between both SUVmax and ADC and clinicopathological prognostic factors3 years

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026